CYPRIUM THERAPEUTICS

Cyprium Therapeutics, Inc. (Cyprium), a Fortress Biotech subsidiary company, is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. In March 2017, Cyprium entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to advance the clinical development of CUTX-101 (Copper Histidinate injection) for the treatment of Menkes disease... Cyprium is a majority-owned subsidiary of Fortress Biotech (NASDAQ: FBIO) and is based in New York City.

Also known as: Cyprium, Cyprium Therapeutics, Inc.

Primary location: New York United States